The National Myelodysplastic Syndromes (MDS) Study
The purpose of this project is to collect blood, bone marrow and other tissues (eyebrow hairs, cells from the inside of the participant¿s cheek (also called buccal cells), and/or skin) and information from participants to investigate how their disease changes over time. This knowledge will allow doctors to better understand how MDS changes over time and may lead to better ways to prevent, detect, and treat MDS.
1. To develop a high-quality clinical database containing clinical history, including environmental exposure history, presenting signs and symptoms, diagnostic testing results, co-existing diseases, therapies and response to therapies, disease progression, quality of life and survival.
2. To develop a high-quality biorepository linked to the clinical data that will facilitate diverse studies, including genetic, epigenetic, immunologic, proteomic, and cell-functional and cell-phenotypic studies through the development of (details described further in the Manual of Procedures):
- Central communication with the biorepository to ensure timely and accurate collections and biospecimen data appended to the clinical database;
- Defined standard operating procedures for the collection, processing, storage and distribution, with special emphasis on processing protocols fit-for-purpose to sample requirements for downstream testing;
- Quality management procedures to ensure minimal numbers of errors in the management of the biospecimens.
3. To facilitate broad use of these linked data and specimens to support studies focused on:
- Improving diagnostic accuracy, risk-stratification and prognostication, and medical decision-making in MDS;
- Understanding quality of life and its relationship to changing disease and treatment status;
- Understanding the pathogenesis of MDS and diverse MDS subtypes, including genetic, epigenetic, immunologic mechanisms;
- Optimizing treatment strategies for specific subtypes of MDS;
- Identifying novel biomarkers for MDS outcomes; and
- Identifying novel targets for therapeutic interventions in MDS.
Suspected (e.g., persistent unexplained cytopenia, circulating peripheral blasts etc.) myelodysplastic syndromes (MDS) or myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorders and undergoing diagnostic work-up with planned bone marrow assessments, or diagnosed with de novo or therapy-related MDS within 6-months of enrollment per the World Health Organization (WHO) criteria1 and undergoing clinical evaluation and planned bone marrow assessments to confirm MDS or to evaluate disease status
Bone marrow aspirate expected to be performed within 1 week of registration, and in all cases must be performed no later than 4 weeks after enrollment
Age 18 or older
B12 level, serum folate, ferritin, and Thyroid-Stimulating Hormone (TSH) tests performed in prior 6 months
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub